Analyst Joseph Pantginis of H.C. Wainwright maintained a Buy rating on Lexicon Pharmaceuticals, retaining the price target of $4.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Joseph Pantginis has given his Buy rating due to a combination of factors including Lexicon Pharmaceuticals’ recent financial performance and strategic advancements in their R&D pipeline. The company reported a positive EPS for the second quarter of 2025, surpassing expectations, and maintains a solid cash position, which supports its ongoing research and development efforts.
Lexicon is making significant progress in its late-stage trials for cardiometabolic conditions, particularly with pilavapadin and sotagliflozin. The successful Phase 2b results for pilavapadin have paved the way for Phase 3 trials, and the company is actively engaging in partnership discussions. Additionally, the global enrollment in the pivotal Phase 3 SONATA-HCM trial is on track, with over 100 active clinical sites. These developments, along with strategic partnerships and licensing agreements, position Lexicon well for future growth, justifying the Buy rating.
Pantginis covers the Healthcare sector, focusing on stocks such as Krystal Biotech, Esperion, and Capricor Therapeutics. According to TipRanks, Pantginis has an average return of -16.3% and a 33.07% success rate on recommended stocks.